Adaptive Biotechnologies COO trades 69K shares
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported option exercises and share sales in a planned series of trades.
Rhea-AI Filing Summary
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported option exercises and share sales in a planned series of trades. She exercised stock options for 56,047 shares of common stock at exercise prices of $7.27 and $12.14 per share and sold 69,061 shares in open‑market transactions at weighted average prices ranging from about $13.39 to $15.48 between April 6 and April 8, 2026. After these transactions, she directly held 434,188 shares of common stock and retained vested stock options representing 37,553 shares. The filing notes that all transactions were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 18, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
12 txns
Insider
RUBINSTEIN JULIE
Role
President and COO
Sold
69,061 shs ($991K)
Approx. gross sale proceeds
$991K
Approx. exercise cost
$465K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 14,722 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 11,881 | $0.00 | $0.00 |
| Exercise | Common Stock | 14,722 | $7.27 | $107K |
| Exercise | Common Stock | 11,881 | $12.14 | $144K |
| Sale | Common Stock | 30,841 | $14.83 | $457K |
| Sale | Common Stock | 100 | $15.48 | $2K |
| Exercise | Stock Option (right to buy) | 14,722 | $0.00 | $0.00 |
| Exercise | Common Stock | 14,722 | $7.27 | $107K |
| Sale | Common Stock | 19,060 | $13.56 | $258K |
| Exercise | Stock Option (right to buy) | 14,722 | $0.00 | $0.00 |
| Exercise | Common Stock | 14,722 | $7.27 | $107K |
| Sale | Common Stock | 19,060 | $14.33 | $273K |
Holdings After Transaction:
Stock Option (right to buy) — 429,211 contracts (Direct);
Common Stock — 434,188 shares (Direct)
Footnotes (5)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
- F2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.05 to $14.86, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F3. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.39 to $13.83, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.45 to $15.21, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F5. The option is fully vested and exercisable.
Key Figures
Shares sold: 69,061 shares
Options exercised: 56,047 shares
Post-trade holdings: 434,188 shares
+4 more
7 metrics
Shares sold
69,061 shares
Total common shares sold in open-market transactions
Options exercised
56,047 shares
Total shares acquired via stock option exercises
Post-trade holdings
434,188 shares
Common shares directly held after transactions
Remaining options
37,553 shares
Vested stock options outstanding after exercises
Option exercise price
$7.27 per share
Exercise price for one stock option grant
Option exercise price
$12.14 per share
Exercise price for another stock option grant
Sale price example
$14.33 per share
Weighted average price for one sale transaction on April 6, 2026
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (right to buy), Exercise or conversion of derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (right to buy) financial
""security_title": "Stock Option (right to buy)""
Exercise or conversion of derivative security financial
""transaction_code_description": "Exercise or conversion of derivative security""
Sale in open market or private transaction financial
""transaction_code_description": "Sale in open market or private transaction""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did ADPT President and COO Julie Rubinstein report?
Julie Rubinstein reported exercising stock options for 56,047 Adaptive Biotechnologies shares and selling 69,061 common shares in open‑market trades. These moves converted options into stock, then into cash, while leaving her with a substantial remaining equity position.
What option exercise prices did ADPT’s COO use in these transactions?
Julie Rubinstein exercised stock options with exercise prices of $7.27 and $12.14 per share. These options were fully vested and exercisable, allowing her to convert them into common stock, which she then partly sold in the open market.
Were Julie Rubinstein’s ADPT stock trades made under a Rule 10b5‑1 plan?
Yes. A footnote states all transactions in this Form 4 were effected under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 18, 2025. Such plans schedule trades in advance and are designed to reduce concerns about trading on nonpublic information.
How many stock options does the ADPT COO still hold after these transactions?
Following the reported option exercises, Julie Rubinstein holds stock options covering 37,553 shares of Adaptive Biotechnologies common stock. The Form 4 notes these remaining options are fully vested and exercisable, with stated expiration dates extending to 2029 and 2032.
AI-generated analysis. How Rhea-AI works. Not financial advice.
